Healthcare [ 10/13 ] | Biotechnology [ 87/159 ]
NASDAQ | Common Stock
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs.
It offers SKYTROFA for treating patients with growth hormone deficiency (GHD).
The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 11, 24 | -1.65 Increased by +55.41% | -2.17 Increased by +23.96% |
| Nov 7, 23 | -2.88 Increased by +4.95% | -2.38 Decreased by -21.01% |
| Sep 5, 23 | -2.16 Decreased by -47.95% | -2.59 Increased by +16.6% |
| Apr 27, 23 | -1.98 Increased by +10.41% | -2.66 Increased by +25.56% |
| Feb 16, 23 | -3.7 Decreased by -97.86% | -2.56 Decreased by -44.53% |
| Nov 2, 22 | -3.03 Decreased by -106.12% | -2.49 Decreased by -21.69% |
| Aug 10, 22 | -1.46 Increased by +41.6% | -2.13 Increased by +31.46% |
| May 11, 22 | -2.21 Decreased by -88.89% | -2 Decreased by -10.5% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 137.7 M Increased by +501.42% | -86.88 M Increased by +58.11% | Decreased by -63.09% Increased by +93.04% |
| Sep 30, 23 | 48.03 M Increased by +214.15% | -162.22 M Increased by +3.98% | Decreased by -337.73% Increased by +69.44% |
| Jun 30, 23 | 47.39 M Increased by +669.37% | -121.43 M Decreased by -49.33% | Decreased by -256.23% Increased by +80.59% |
| Mar 31, 23 | 33.59 M Increased by +391.93% | -110.91 M Increased by +11.62% | Decreased by -330.21% Increased by +82.03% |
| Dec 31, 22 | 22.9 M Increased by +367.55% | -207.42 M Decreased by -95.56% | Decreased by -905.91% Increased by +58.17% |
| Sep 30, 22 | 15.29 M Increased by +1.27 K% | -168.96 M Decreased by -110.28% | Decreased by -1.11 K% Increased by +84.69% |
| Jun 30, 22 | 6.16 M Increased by +502.74% | -81.32 M Increased by +39.48% | Decreased by -1.32 K% Increased by +89.96% |
| Mar 31, 22 | 6.83 M Increased by +815.28% | -125.5 M Decreased by -99.86% | Decreased by -1.84 K% Increased by +78.16% |